맞춤형 의료 시장 규모는 2024년 1,302억 3,000만 달러로 평가되었으며, 2024-2031년간 10.67%의 연평균 복합 성장률(CAGR)로 성장하여 2031년에는 2,725억 9,000만 달러에 달할 것으로 예상됩니다. 맞춤형 의료(정밀의료라고도 함)는 예방, 진단, 치료와 같은 의료 의사결정을 개인의 특정 유전적 구성 및 기타 개인적 특성에 맞게 조정하는 의료 접근법입니다. 이 치료법은 유전자 검사 및 바이오마커를 통해 얻은 데이터를 사용하여 치료법을 최적화하고 환자가 가장 효과적이고 부작용이 적은 의약품을 받을 수 있도록 하는 것입니다.
맞춤형 의료의 적용에는 유전자 프로파일을 기반으로 개인에게 가장 적합한 약물과 용량을 결정하는 약리유전체학, 고유한 분자 표적에 초점을 맞춘 특정 암에 대한 표적 치료, 특정 질병에 대한 유전적 소인에 기반한 예방 조치 등이 있습니다.
또한, 맞춤형 의료는 인간 유전체 프로젝트와 같은 프로그램에서 얻은 첨단 기술과 데이터를 활용하여 보다 정확하고 전문적인 치료를 제공함으로써 환자의 결과를 개선할 수 있습니다.
맞춤형 의료 시장을 형성하는 주요 시장 역학
암 및 유전성 질환의 유병률 증가:
암과 유전성 질환의 유병률 증가로 맞춤형 의료 기술의 필요성이 대두되고 있습니다. 세계보건기구(WHO)에 따르면, 암은 세계 최대 사망 원인으로 2020년에는 약 1,000만 명이 사망할 것으로 예상됩니다. 국제암연구소(IARC)는 2040년 전 세계 암 환자 수가 2020년 대비 47% 증가한 2,840만 명에 달할 것으로 예측했습니다. 암 부담 증가는 표적 치료와 개인 맞춤형 치료 접근법의 개발을 촉진하고 있습니다.
유전체 시퀀싱 기술의 발전 :
유전자 염기서열 분석 기술의 급속한 발전으로 맞춤형 의료가 더욱 친숙하고 저렴해지고 있으며, National Human Genome Research Institute에 따르면 인간 유전체 염기서열 분석 비용은 2001년 약 1억 달러에서 2021년까지 1,000달러 미만으로 크게 감소할 것으로 예상됩니다. 이러한 대폭적인 비용 절감은 임상 현장에서 유전자 검사의 사용을 증가시켜 개인 맞춤형 치료 옵션을 가능하게 했습니다.
정밀의료 이니셔티브에 대한 투자 증가:
정부와 기업은 정밀의료 연구와 실행에 대한 투자를 늘리고 있습니다. 예를 들어, 미국 국립보건원(NIH)은 100만 명 이상의 미국인으로부터 데이터를 수집하여 연구를 가속화하고 건강 결과를 개선하기 위해 All of Us 연구 개발 프로그램을 개발했으며, 2023년 9월 현재 이 프로그램은 74만 6천 명 이상을 등록하고 48만 2천 명 이상이 유전체 분석을 위해 생체 샘플을 제출하고 있습니다. 이 대규모 시도는 맞춤형 의료 접근법 확대에 대한 관심 증가를 반영하고 있습니다.
주요 과제
보건의료 격차:
맞춤형 의료는 주로 유럽인 집단에서 얻은 유전체 데이터를 기반으로 하기 때문에 다양한 인종 및 민족 그룹에 대한 치료 효과의 편차가 발생합니다. 이러한 과소 평가는 다양한 배경을 가진 환자의 반응을 확실하게 예측할 수 없는 알고리즘으로 이어져 기존의 의료 격차를 확대시킵니다.
규제 감독:
맞춤형 의료기술이 발전함에 따라 기존 치료와 비교하여 그 안전성과 유효성을 평가하기 위해서는 규제기관의 새로운 기준 개발이 필요합니다. 여기에는 유전자 및 바이오마커 데이터를 임상 진료에 통합하기 위한 가이드라인 개발도 포함됩니다. 이러한 혁신의 임상적 효과와 비용 효율성을 평가할 수 있는 확립된 절차가 존재하지 않는 것은 혁신의 승인과 광범위한 수용을 방해하고 이 분야의 발전을 제한하고 있습니다.
주요 동향 :
유전체 진단과 표적 치료의 통합:
병원은 이러한 첨단 기술의 사용 빈도가 높아짐에 따라 환자별 DNA 프로파일에 기반한 맞춤 치료 계획을 제공할 수 있게 되었습니다. 이러한 추세는 의료 개입의 정확성을 높이고, 특정 종양 특성에 맞는 약물 투여가 가능한 암과 같은 질병을 보다 효과적으로 관리할 수 있게 하며, 궁극적으로 환자의 결과와 만족도를 향상시킬 수 있습니다.
디지털 헬스 솔루션 투자 확대:
디지털 헬스 솔루션 투자 확대:원격 의료, 모바일 건강 앱, 웨어러블 기기의 등장으로 환자의 건강 데이터를 지속적으로 모니터링하고 치료 프로그램을 실시간으로 변경할 수 있게 되었습니다. 이러한 기술은 환자의 건강 상태와 치료 반응에 대한 정보를 제공함으로써 환자에게 힘을 실어주고, 의료에 대한 보다 협력적인 접근 방식을 촉진하며, 맞춤 치료 요법에 대한 순응도를 향상시킵니다.
맞춤 영양 및 웰빙:
맞춤형 영양과 웰빙에 대한 관심이 높아지면서 맞춤형 의료 시장의 중요한 분야로 부상하고 있습니다. 고객의 건강에 대한 인식이 높아짐에 따라 특정 유전적 프로파일과 건강 문제에 대응하는 맞춤형 영양 요법 및 건강 보조 식품에 대한 수요가 증가하고 있습니다. 이러한 추세는 식습관이 건강과 질병 관리에 미치는 영향에 대한 보다 종합적인 이해를 반영하고 있으며, 그 결과 특정 건강 문제를 해결하면서 전반적인 건강을 증진하는 독창적인 솔루션이 등장하고 있습니다.
Personalized Medicine Market size was valued at USD 130.23 Billion in 2024 and is projected to reach USD 272.59 Billion by 2031 , growing at a CAGR of 10.67% from 2024 to 2031. Personalized medicine, also known as precision medicine, is a medical approach that tailors healthcare decisions-such as prevention, diagnosis, and treatment-to an individual's specific genetic composition and other personal traits. This practice uses data from genetic testing and biomarkers to optimize therapeutic actions, ensuring that patients receive the most effective medicines with the fewest negative effects.
Personalized medicine applications include pharmacogenomics, which helps determine the best medications and dosages for individuals based on their genetic profiles; targeted therapies for specific cancers that focus on unique molecular targets; and preventive measures informed by genetic predisposition to certain diseases.
Furthermore, personalized medicine uses advanced technologies and data from programs such as the Human Genome Project to improve patient outcomes by providing more precise and specialized treatment
The key market dynamics that are shaping the personalized medicine market include:
Increasing Prevalence of Cancer and Genetic Disorders:
The increased prevalence of cancer and genetic disorders is pushing the need for personalized medicine techniques. According to the World Health Organization (WHO), cancer is the biggest cause of death worldwide, accounting for approximately 10 million deaths in 2020. The International Agency for Research on Cancer (IARC) predicts that the worldwide cancer burden will reach 28.4 million cases in 2040, up 47% from 2020. The increasing cancer burden is driving the development of targeted treatments and personalized treatment approaches.
Advancements in Genomic Sequencing Technologies:
Rapid advancements in genetic sequencing technology are making customized medicine more accessible and inexpensive. According to the National Human Genome Research Institute, the cost of sequencing a human genome has decreased drastically, from approximately USD 100 Million in 2001 to less than $1,000 in 2021. This large cost reduction has resulted in increased usage of genetic testing in clinical settings, allowing for personalized treatment options.
Growing Investment in Precision Medicine Initiatives:
Governments and corporate entities are increasing their investments in precision medicine research and implementation. For example, the National Institutes of Health (NIH) in the United States developed the All of Us Research Program, which intends to collect data from one million or more Americans to speed up research and improve health outcomes. As of September 2023, the initiative had registered over 746,000 people, with over 482,000 submitting biosamples for genomic analysis. This large-scale endeavor reflects the growing interest in expanding personalized medicine approaches.
Key Challenges:
Healthcare Disparities:
Personalized medicine is based primarily on genomic data from European populations, which leads to therapeutic efficacy biases for varied racial and ethnic groups. This underrepresentation leads to algorithms that do not reliably anticipate reactions from patients from various backgrounds, increasing existing healthcare disparities.
Regulatory Oversight:
The development of new standards by regulatory bodies is necessary as personalized medicine technologies progress to assess their safety and effectiveness in comparison to conventional treatments. This includes developing guidelines for integrating genetic and biomarker data into clinical practice. The absence of established procedures for evaluating the clinical and cost-effectiveness of these innovations hampers their approval and widespread acceptance, limiting progress in this field.
Key Trends:
Integration of Genomic Diagnostics and Targeted Therapies:
Hospitals can now offer individualized treatment plans based on patient's unique DNA profiles as they use these cutting-edge technologies more frequently. This trend increases the accuracy of medical interventions, allowing for more effective disease management, such as cancer, where medications can be tailored to specific tumor characteristics, ultimately increasing patient outcomes and satisfaction.
Growing Investment in Digital Health Solutions:
The advent of telemedicine, mobile health apps, and wearable devices has enabled continuous monitoring of patient health data, allowing for real-time alterations to treatment programs. These technologies empower patients by providing them with information on their health and treatment responses, promoting a more collaborative approach to healthcare and increasing adherence to individualized treatment regimens.
Personalized Nutrition and Wellness:
There is a growing emphasis on tailored nutrition and wellness, which is emerging as a crucial area of the personalized medicine market. As customers become more health-conscious, there is a growing need for personalized dietary regimens and supplements that address specific genetic profiles and health concerns. This trend reflects a more comprehensive understanding of how diet affects health and illness management, resulting in creative solutions that promote overall well-being while addressing specific health concerns.
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
Here is a more detailed regional analysis of the personalized medicine market:
Asia Pacific:
According to Verified Market Research, the Asia Pacific region is estimated to exhibit the highest growth within the market during the forecast period. The increased frequency of cancer and genetic illnesses in the Asia Pacific region is driving demand for personalized medical strategies. According to the International Agency for Research on Cancer (IARC), Asia accounted for over half of all new cancer cases worldwide in 2020, with an estimated 8.9 million new cases. According to the IARC, by 2040, this number will climb to around 14.5 million new cases per year in Asia. This rising cancer burden is driving investments in genetic research and personalized treatment strategies throughout the region.
Furthermore, the Asia Pacific region's population is rapidly growing and aging, creating demand for personalized healthcare solutions. According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), the region's population is predicted to grow from 4.3 billion in 2020 to 4.7 billion in 2050. Also, the population aged 65 and up is expected to more than quadruple, from 395 million in 2020 to 956 million by 2050. This generational transition is increasing the demand for more tailored and effective medical treatments, hence boosting the personalized medicine market.
North America:
North America is estimated to dominate the personalized medicine market during the forecast period. North America, particularly the United States, has a significant burden of chronic diseases that can be addressed using personalized medicine approaches. According to the Centers for Disease Control and Prevention (CDC), six out of every ten persons in the United States have a chronic disease, with four out of ten having two or more. In 2019, around 37.3 million Americans (11.3% of the total population) had diabetes. The rising frequency of chronic diseases creates a desire for more targeted and effective therapies provided by personalized medicine.
Furthermore, North America has a well-developed healthcare infrastructure that easily accepts new technology, helping the adoption of personalized medicine. According to the US Food and Drug Administration (FDA), the number of approved personalized medicines has increased significantly. In 2022, personalized medicines accounted for 25% of all new drug approvals, up from 5% in 2005. This trend reflects the region's ability to translate research into practical applications, hence boosting the expansion of the personalized medicine market.
The Personalized Medicine Market is segmented based on Product, End-User, and Geography.
Based on Product, the market is segmented into Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Personalized Medical Care, and Personalized Nutrition & Wellness. The personalized medicine diagnostics segment is estimated to dominate the personalized medicine market. This dominance is primarily driven by the growing demand for improved diagnostic tools capable of detecting genetic variants and biomarkers associated with a variety of disorders, including cancer. The rising frequency of chronic diseases needs more precise diagnostic procedures, resulting in increased investment in genetic testing and direct-to-consumer diagnostics.
Based on End-User, the Personalized Medicine Market is divided into Hospitals, Diagnostic Centers, Research & Academic Institutes, and Others. The hospital segment is estimated to dominate the market over the forecast period due to hospitals' crucial role as key providers of personalized healthcare services, which incorporate genomic diagnostics and tailored medicines into patient care. Their specialized facilities and skills enable them to efficiently implement innovative treatment approaches, thereby driving the expansion of personalized medicine and determining its future clinical practice.
Based on Geography, the Personalized Medicine Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America is estimated to dominate the market during the forecasted period due to the region's superior healthcare infrastructure, significant R&D investments, and high rates of chronic diseases such as cancer and diabetes. Furthermore, the substantial presence of top biotech and pharmaceutical businesses promotes innovation and acceptance of customized medicine solutions, firmly establishing North America as a market leader.
Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.